Therefore, we hypothesized that ANXA1 could be of therapeutic use in Alzheimer’s disease by regulating blood–brain barrier leakage, reducing microvascular damage and amyloid-β pathology. Here, ANXA1 is linked to early-onset autosomal dominant Alzheimer disease.